Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
This article was originally published in SRA
Executive Summary
More time is needed to gauge whether the US Food and Drug Administration's rare pediatric disease priority review voucher program has actually encouraged the development of new treatments, the Government Accountability Office believes. The FDA, however, isn't interested in giving the incentive program any more time to try to prove itself.
You may also be interested in...
Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.
Rare Disease Supporters Suggest Permanent PRV Program, Even If It May Concern FDA
Non-profit biotech founder says permanent pediatric rare disease priority review voucher program will boost incentive, but FDA is concerned about resource drain vouchers cause.
Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?